Novo Nordisk on Tuesday announced plans to cut the list price of its popular diabetes and weight-loss drugs Ozempic and Wegovy by as much as 50% in the U.S. next year. The Danish drugmaker indicated the price cuts will be effective on Jan. 1, 2027, and the timing will coincide with new, lower prices for Ozempic and Wegovy under Medicare plans for older Americans.The company's announcement indicated the list price for various doses of its Ozempic and Wegovy medicines will be lowered to $675, which represents ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?AFRS is a condition characterized by allergic hypersensitivity to fungi, which often leads to chronic sinus issues and surgery.The approval covers Dupixent for patients aged six years and older with a history of sino-nasal surgery.The approval is based on Phase 3 trial results that demonstrated Dupixent’s effectiveness in reducing nasal symptoms and the need for systemic corticosteroids or surgery compared to placebo.Dupi ...

I have covered Tarsus Pharmaceuticals ( TARS ) several times, highlighting the company as a Buy due to the robust growth of Xdemvy. Since my first article one year ago, the stock has risen from $47 to $75, a 60% gainBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee a ...

Keytruda's been driving Merck's growth for nearly a decade, accounting for almost half of the company's total sales last year. But new US federal drug pricing policies will bring lower-priced competitors into the market within the next few years. The drug giant has been working hard to diversify its pipeline and has some promising new treatments, including a more effective pneumonia vaccine Capvaxive and a novel lung disease treatment Winrevair.To help the performance of its new products stand out, Merck w ...

Key Takeaways AXSM reported a Q4 loss of 71 cents, missing estimates even as revenues rose 65% to $196M.Auvelity sales climbed 68% Y/Y to $155.1M, with prescriptions up 42% year over year in Q425.Axsome's Sunosi sales rose 40% Y/Y, while newly launched Symbravo generated $4.1M in Q4.Axsome Therapeutics (AXSM) incurred a loss of 71 cents per share in the fourth quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 70 cents. The company had incurred a loss of 96 cents per share in the year-ago ...

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the affordability and accessibility of ARAKODA (tafenoquine), the only FDA-approved, once-weekly prescription medication for malaria prevention in the US. The collaboration allows eligible patients to save up to 30% on the treatment at over 70,000 pharmacies nationwide. This initiative is a key part of the company’s st ...

Key Takeaways Lilly's Mounjaro and Zepbound drove $36.5B in 2025 sales, fueling strong cardiometabolic growth.Novo Nordisk expects 2026 sales and operating profit to decline amid competition and pricing pressure.LLY shares rose 17.4% in a year, while NVO plunged 56.4%.Novo Nordisk (NVO) and Eli Lilly (LLY) lead the diabetes and obesity market, driven by blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk m ...

Kiniksa outlined several commercial priorities for 2026, including physician education and marketing initiatives designed to broaden awareness and support earlier use in the disease course. Moat said the company plans to:Management attributed ARCALYST’s growth primarily to expanding adoption of IL-1 pathway inhibition as a second-line treatment immediately after failure of NSAIDs and colchicine. Moat pointed to the publication of the 2025 ACC Concise Clinical Guidance , which he said recommends IL-1 pathway ...

Key Takeaways SMMT reported a wider Q4 loss of 29 cents per share, with no revenues recorded in 2025.Summit Therapeutics boosted R&D 117% to advance ivonescimab across late-stage NSCLC studies.SMMT's FDA-accepted BLA for ivonescimab in NSCLC faces a decision by Nov. 14, 2026.Summit Therapeutics (SMMT) reported fourth-quarter 2025 loss per share of 29 cents, wider than the Zacks Consensus Estimate of 22 cents. In the year-ago period, the company had incurred a loss of 8 cents per share.The reported loss incl ...